Chicoric Acid

Chicoric Acid

SCHEMBL730803

O=C(/C=C/c1ccc(O)c(O)c1)OC(C(=O)O)C(OC(=O)/C=C/c1ccc(O)c(O)c1)C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 7/20 1.00
TDP1 Q9NUW8 6/20 1.00
ALOX15 P16050 3/20 1.00
TP53 P04637 2/20 1.00
SRC P12931 2/20 0.84
APP P05067 8/20 0.65
KDM4E B2RXH2 6/20 0.65
TTR P02766 6/20 0.65
MAPT P10636 5/20 0.65
HPGD P15428 4/20 0.65
AKR1B1 P15121 4/20 0.65
POLB P06746 3/20 0.65
GAA P10253 3/20 0.65
RECQL P46063 2/20 0.65
MMP1 P03956 2/20 0.65
THRB P10828 2/20 0.65
APEX1 P27695 2/20 0.65
CYP1A2 P05177 2/20 0.65
LCK P06239 2/20 0.65
FYN P06241 2/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Chicoric Acid SCHEMBL13772650 1.00 HSD17B10 (1.00) HSD17B10TDP1ALOX15TP53SRC
Chicoric Acid SCHEMBL30518333 1.00 HSD17B10 (1.00) HSD17B10TDP1ALOX15TP53SRC
Chicoric Acid SCHEMBL964775 1.00 HSD17B10 (1.00) HSD17B10TDP1ALOX15TP53SRC
Cichoric Acid SCHEMBL29349701 1.00 HSD17B10 (1.00) HSD17B10TDP1ALOX15TP53SRC
Chicoric Acid SCHEMBL30995918 1.00 HSD17B10 (1.00) HSD17B10TDP1ALOX15TP53SRC
Cichoric Acid SCHEMBL29385936 1.00 HSD17B10 (1.00) HSD17B10TDP1ALOX15TP53SRC
Chicoric Acid SCHEMBL963407 1.00 HSD17B10 (1.00) HSD17B10TDP1ALOX15TP53SRC
Chicoric Acid SCHEMBL961606 1.00 HSD17B10 (1.00) HSD17B10TDP1ALOX15TP53SRC
Chicoric Acid SCHEMBL21176639 1.00 HSD17B10 (1.00) HSD17B10TDP1ALOX15TP53SRC
Cichoric Acid SCHEMBL15532218 1.00 HSD17B10 (1.00) HSD17B10TDP1ALOX15TP53SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11717549-B2 Steviol glycoside solubility enhancers CARGILL, INCORPORATED (US) 2023-08-08 US disclosed
US-20200171331-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING CAFFEIC ACID CHELATES ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY 2020-06-04 US disclosed
WO-2020077428-A1 COMPOUNDS, USE OF COMPOUNDS IN THE PREPARATION OF A PHARMACEUTICAL COMPOSITION, AND PHARMACEUTICAL COMPOSITION COMPRISING 7,11B-DIHYDRO-6H-INDENO[2,1-C]CHROMENE-3,6A,9,10-TETROL, NEUTRAL OR IONIZED DERIVATIVES OR ANALOGUES THEREOF, FOR SENOLYTIC PREVENTION AND/OR THERAPY PURPOSES UNIÃO BRASILEIRA DE EDUCAÇÃO E ASSISTÊNCIA - MANTENEDORA DA PUCRS (BR) 2020-04-23 WO disclosed
US-20190223481-A1 STEVIOL GLYCOSIDE SOLUBILITY ENHANCERS CARGILL, INCORPORATED (US) 2019-07-25 US disclosed
US-20170258861-A1 Treatment of Herpes, Pseudomonas, Staph, and Hepatitis SQUIRES MERYL J (US) 2017-09-14 US disclosed
US-9662360-B2 Treatment of herpes, pseudomonas, staph, and hepatitis MERITUS CORPORATION (DM) 2017-05-30 US disclosed
US-9491962-B2 Use of chicoric acid and derivatives for regulating skin pigmentation NESTEC S.A. (CH) 2016-11-15 US disclosed
US-9491962-B2 Use of chicoric acid and derivatives for regulating skin pigmentation NESTEC S.A. (CH) 2016-11-15 US disclosed
US-20160151436-A1 Treatment of Herpes, Pseudomonas, Staph, and Hepatitis MERITUS CORPORATION (DM) 2016-06-02 US disclosed
US-9192554-B2 Use of chicoric acid and lactic bacterium in food supplement for regulating skin pigmentation NESTEC S.A. (CH) 2015-11-24 US disclosed
WO-2012000962-A2 USE OF CHICORIC ACID AND LACTIC BACTERIUM IN FOOD SUPPLEMENT FOR REGULATING SKIN PIGMENTATION NESTEC S.A. (CH) 2012-01-05 WO disclosed
WO-2012000957-A1 USE OF CHICORIC ACID AND LACTIC BACTERIUM FOR REGULATING SKIN PIGMENTATION NESTEC S.A. (CH) 2012-01-05 WO disclosed
WO-2012000954-A1 USE OF CHICORIC ACID AND DERIVATIVES FOR REGULATING SKIN PIGMENTATION NESTEC S.A. (CH) 2012-01-05 WO disclosed
US-20110280848-A1 COMPOSITION COMPRISING CHICORIC ACID AND/OR DERIVATIVES THEREOF NESTEC S.A. (CH) 2011-11-17 US disclosed
US-20110280848-A1 COMPOSITION COMPRISING CHICORIC ACID AND/OR DERIVATIVES THEREOF NESTEC S.A. (CH) 2011-11-17 US disclosed
US-20100303935-A1 Medicinal Composition MCGINLEY PARTNERS, LLC (US) 2010-12-02 US disclosed
US-20100303935-A1 Medicinal Composition MCGINLEY PARTNERS, LLC (US) 2010-12-02 US disclosed
WO-2010086322-A1 COMPOSITION COMPRISING CHICORIC ACID AND/OR DERIVATIVES THEREOF NESTEC S.A. (CH) 2010-08-05 WO disclosed
EP-2210504-A1 Composition comprising chicoric acid and/or derivatives thereof Nestec S.A. (CH) 2010-07-28 EP disclosed
US-20090191288-A1 Composition to Treat Herpes, Pseudomonas, Staph, Hepatitis and Other Infectious Diseases SQUIRES MERYL J 2009-07-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160151436-A1 Treatment of Herpes, Pseudomonas, Staph, and Hepatitis NISCH, CUTA, HRH1 HSD17B10 1652/4885TDP1 4114/4885ALOX15 1816/4885
US-20170258861-A1 Treatment of Herpes, Pseudomonas, Staph, and Hepatitis NISCH, CUTA, HRH1 HSD17B10 1652/4885TDP1 4114/4885ALOX15 1816/4885
US-20090191288-A1 Composition to Treat Herpes, Pseudomonas, Staph, Hepatitis and Other Infectious Diseases ASPH, KCNH3, PRPH HSD17B10 1798/4885TDP1 4091/4885ALOX15 1448/4885
US-20100303935-A1 Medicinal Composition MUSK, TNNC1, ACHE HSD17B10 3405/4885TDP1 1158/4885ALOX15 318/4885
US-20200171331-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING CAFFEIC ACID CHELATES PROC, PRCP, CTSG HSD17B10 1863/4885TDP1 3124/4885ALOX15 3099/4885
US-11717549-B2 Steviol glycoside solubility enhancers SI, TAS2R7, TAS2R31 HSD17B10 827/4885TDP1 1913/4885ALOX15 2972/4885
US-20110280848-A1 COMPOSITION COMPRISING CHICORIC ACID AND/OR DERIVATIVES THEREOF LCT, LDHA, SI HSD17B10 595/4885TDP1 1032/4885ALOX15 2217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.